Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological diagnosis of Advanced biliary malignancy~* The expected survival period is ≥3 months~* Patients with non-extensive metastases~* Except for the lesions to be radiotherapy, there is at least one measurable lesion~* tumor lesions are suitable for radiotherapy~* Have previously received platinum, gemcitabine or 5-FU drugs as first-line treatment, but have not used PD-1/PD-L1 monoclonal antibody treatment~* In the 7 days before enrollment, the Child Pugh score of liver function is 7 or less~Exclusion Criteria:~* Patients with other malignant tumors~* Participated in other drug clinical trials within four weeks~* Clinical diagnosis of severe biliary obstruction or digestive tract obstruction in the past month~* Unstable angina pectoris~* Immunodeficiency~* Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia~* Patients who need to use corticosteroids~* Serious chronic autoimmune diseases~* Ulcerative enteritis, Crohn's disease and other inflammatory bowel diseases~* Inflammatory and chronic diarrheal diseases such as irritable bowel syndrome;~* Sarcoidosis or tuberculosis~* Patients with hypersensitivity to human or murine monoclonal antibodies~* Pregnant and lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- tislelizumab combined with radiotherapy (Type: EXPERIMENTAL): To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.

Based on this trial design, predict the completion outcome and termination type (if applicable).